Synthetic arylquinuclidine derivatives exhibit antifungal activity against Candida albicans, Candida tropicalis and Candida parapsilopsis

Annals of Clinical Microbiology and Antimicrobials

Volumn 10, Issue , 2011, Pages

  Ishida, Kelly ^a   Fernandes Rodrigues, Juliany C ^a   Cammerer, Simon ^b   Urbina, Julio A ^c   Gilbert, Ian ^b   de Souza, Wanderley ^a,d   Rozental, Sonia ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^d INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1' [4' (BENZYLOXY) PHENYL]] QUINUCLIDIN 2 ENE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ARYLQUINUCLIDINE DERIVATIVE; FLUCONAZOLE; ITRACONAZOLE; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; WSP 1261; WSP 1262; WSP 1263; WSP 1264; WSP 1265; WSP 1266; WSP 1267; WSP 1268; WSP 1269; WSP 889; ENZYME INHIBITOR; FUNGAL PROTEIN; QUINUCLIDINE DERIVATIVE; SQUALENE SYNTHASE;

ANIMAL CELL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOPSIS; CANDIDA TROPICALIS; CELL MEMBRANE; CELL SIZE; CELL VACUOLE; CYTOPLASM; FLUORESCENCE MICROSCOPY; FUNGAL CELL; FUNGICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TRANSMISSION ELECTRON MICROSCOPY; VERO CELL; CANDIDIASIS; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; SYNTHESIS;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDA TROPICALIS; CANDIDIASIS; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; FUNGAL PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; QUINUCLIDINES;

EID: 78651581722     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-10-3     Document Type: Article

References (36)

1. Colombo AL, Nucci M, Park BJ, Noue'R SA, Arthington-Skaggs B, Matta DA, Warnock D, Morgan J. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006, 44:2816-2823. 10.1128/JCM.00773-06, 1594610, 16891497.
2. Kauffman CA. Fungal infections. Proc Am Thoracic Soc 2006, 3:35-40.
3. Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. Trends in Microbiol 2003, 11:272-279.
4. Canuto MM, Rodero FG. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002, 2:550-563. 10.1016/S1473-3099(02)00371-7, 12206971.
5. Gonzalez-Pacanowska D, Arison B, Havel CM, Watson JA. Isopentenoid synthesis in isolated embryonic Drosophila cells. Farnesol catabolism and -oxidation. J Biol Chem 1988, 26:1301-1306.
6. Tavridou A, Manolopoulos VG. EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors. Curr Pharm Biotechnol 2009, 15:3167-3178.
7. McTaggart F, Brown GR, Davidson RG, Freeman S, Holdgate GA, Mallion KB, Mirrlees DJ, Smith GJ, Ward WH. Inhibition of squalene synthase of rat liver by novel 3'-sustituted quinuclidines. Biochem Pharmacol 1996, 51:1477-1487. 10.1016/0006-2952(96)00089-5, 8630089.
8. Martins-Duarte ES, Urbina JA, De Souza W, Vommaro RC. Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro. J Antimicrob Chemother 2006, 58:59-65. 10.1093/jac/dkl180, 16702175.
9. Rodrigues JCF, Bernardes CF, Visbal G, Urbina JA, Vercesi AE, De Souza W. Sterol methenyl transferase inhibitors alter the ultrastructure and function of the Leishmania amazonensis mitochondrion leading to potent growth inhibition. Protist 2007, 158:447-456. 10.1016/j.protis.2007.05.004, 17719843.
10. Rodrigues JCF, Concepcion JL, Rodrigues C, Caldera A, Urbina JA, De Souza W. In Vitro Activities of ER-119884 and E5700, Two Potent Squalene Synthase Inhibitors, against Leishmania amazonensis: Antiproliferative, Biochemical, and Ultrastructural Effects. Antimicrob Agents Chemother 2008, 52:4098-4114. 10.1128/AAC.01616-07, 2573141, 18765694.
11. Urbina JA, Concepcion JL, Rangel S, Visbal G, Lira R. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania Mexicana. Mol Biochem Parasitol 2002, 125:35-45. 10.1016/S0166-6851(02)00206-2, 12467972.
12. Urbina JA, Concepcion JL, Caldera A, Payares G, Sanoja C, Otomo T, Hiyoshi H. In Vitro and i Activities of E5700 and ER-11984884, Two Novel Orally Active Squalene Synthase Inhibitors, against Trypanosoma cruzi. Antimicrob Agents Chemother 2004, 2379-2387. 10.1128/AAC.48.7.2379-2387.2004, 434216, 15215084.
13. Bergstrom JD, Kurtz MM, Rew DJ, Amend AM, Karkas JD, Bostedor RG, Bansal VS, Dufresne C, Vanmiddlesworth FL, Hensens OD, Liesch JM, Zink DL, Wilson KE, Onishi J, Milligan JA, Bills G, Kaplan L, Omstead MN, Jenkins RG, Huang L, Meinz MS, Quinn L, Burg RW, Kong YL, Mochales S, Mojena M, Martin I, Pelaez F, Diez MT, Alberts AW. Zaragozic acids--a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci USA 1993, 90:80-84. 10.1073/pnas.90.1.80, 45603, 8419946.
14. Brown GR, Clarke DS, Foubister AJ, Freeman S, Harrison PJ, Johnson MC, Mallion KB, McCormick J, McTaggart F, Reid AC, Smith GJ, Taylor MJ. Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem 1996, 39:2971-2979. 10.1021/jm950907l, 8709131.
15. Cammerer SB, Jimenez C, Jones S, Gros L, Lorente SO, Rodrigues C, Rodrigues JCF, Caldera A, Perez LMR, De Souza W, Kaiser M, Brun R, Urbina JA, Pacanowska DG, Gilbert IH. Quinuclidine derivatives as potential antiparasitics. Antimicrob Agents Chemother 2007, 51:4049-4061. 10.1128/AAC.00205-07, 2151445, 17709461.
16. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts. Aproved standard CLSI document M27-A3. 2008, Clinical and Laboratory Standards Institute, Wayne, PA, Clinical and Laboratory Standards Institute.
17. Pfaller MA, Sheehan DJ, Rex JH. Determination of Fungicidal Activities against Yeasts and Molds: Lessons Learned from Bactericidal Testing and the Need for Standardization. Clin Microbiol Rev 2004, 17:268-280. 10.1128/CMR.17.2.268-280.2004, 387411, 15084501.
18. Lin Z, Hoult J, Raman A. Sulforhodamine B assay for measuring proliferation of a pigmented melanocyte cell line and its application to the evaluation of crude drugs used in the treatment of vitiligo. J Ethnopharmacol 1999, 66:141-150. 10.1016/S0378-8741(98)00199-8, 10433470.
19. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47:3149-3154. 10.1128/AAC.47.10.3149-3154.2003, 201160, 14506023.
20. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin SK, Morgan J, Rodriguez-Tudela JL, Warnock DW, Pahissa A. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835. 10.1128/JCM.43.4.1829-1835.2005, 1081396, 15815004.
21. Pinto PM, Weikert-Oliveira RCB, Lyon JP, Cury VF, Arantes RR, Koga-Ito CY, Resende MA. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis. Microbiol Res 2008, 163:579-585. 10.1016/j.micres.2006.08.007, 16962755.
22. Alves SH, Da Matta DA, Azevedo AC, Loreto ES, Boff E, Santurio JM, Guarro J. In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates. Mycoses 2006, 49:220-225. 10.1111/j.1439-0507.2006.01226.x, 16681814.
23. Lóránd T, Kocsis B. Recent advances in antifungal agents. Mini Rev Med Chem 2007, 7:900-911.
24. De Souza W, Rodrigues JCF. Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs. Interdiscip Perspect Infect Dis 2009, 2009:1-19.
25. Chin NX, Weitzman I, Della-Latta P. In Vitro Activity of Fluvastatin, a Cholesterol-Lowering Agent, and Synergy with Fluconazole and Itraconazole against Candida Species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997, 41:850-852. 163809, 9087504.
26. Ishida K, Rodrigues JCF, Ribeiro MD, Vila TVM, De Souza W, Urbina JA, Nakamura CV, Rozental S. Growth inhibition and ultrastructural alterations induced by Δ24(25)-sterol methyltransferase inhibitors in Candida spp. isolates, including non-albicans organisms. BMC Microbiol 2009, 9:74-85. 10.1186/1471-2180-9-74, 2679025, 19379501.
27. Lorente SO, Gomez R, Jimenez CJ, Cammerer S, Yardley V, de Luca-Fradley K, Croft SL, Ruiz-Perez LM, Urbina JA, Gonzalez-Pacanowska D, Gilber IH. Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg Med Chem 2005, 13:3519-3529. 10.1016/j.bmc.2005.02.060, 15848765.
28. Rodrigues JCF, Urbina J, De Souza W. Antiproliferative and ultrastructural effects of BPQ-OH, a specific inhibitor of squalene synthase, on Leishmania amazonensis. Exp Parasitol 2005, 111:230-238. 10.1016/j.exppara.2005.08.006, 16198340.
29. Hiyoshi H, Yanachimachi M, Ito M, Yasuda N, Okada T, Ikuta H, Shinmyo D, Tanaka K, Kurusu N, Yoshida I, Abe S, Saeki T, Tanaka H. Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. J Lipid Res 2003, 44:128-135. 10.1194/jlr.M200316-JLR200, 12518031.
30. Palmié-Peixoto I, Rocha MR, Urbina JA, De Souza W, Einicker-Lamas M, Motta MCM. Effects of sterol biosynthesis inhibitors on endosymbiont-bearing trypanosomatids. Fems Microbiol Lett 2006, 255:33-42.
31. Dahl CE, Biemann HP, Dhal JS. A protein kinase antigenically related to pp60v-src possible involved in yeast cell cycle control: positive in vivo regulation by sterol. Proc Natl Acad Sci USA 1987, 84:4012-4016. 10.1073/pnas.84.12.4012, 305011, 2438691.
32. Jennings SM, Tsay YH, Fisch TM, Robinson GW. Molecular cloning and characterization of the yeast gene for squalene syntase. Proc Natl Acad Sci USA 1991, 88:6038-6042. 10.1073/pnas.88.14.6038, 52017, 2068081.
33. Bellanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997, 41:1840-1842. 164020, 9257776.
34. Koul A, Vitullo J, Reyes G, Ghannoum M. Effects of voriconazole on Candida glabrata in vitro. J Antimicrob Chemother 1999, 44:109-112. 10.1093/jac/44.1.109, 10459817.
35. Borges M, Van de Ven MA. Degenerative changes after itraconzole treatment. Rev Infect Dis 1987, 9(Suppl 1):S33-42.
36. Hazen KC, Mandell G, Coleman E, Giangqin W. Influence of fluconazole at subinhibitory concentrations on cell surface hydrophobicity and phagocytosis of Candida albicans. FEMS Microbiology Letters 2000, 183:89-94. 10.1111/j.1574-6968.2000.tb08938.x, 10650207.